Blue Bell Private Wealth Management’s Arbutus Biopharma ABUS Stock Holding History

Blue Bell Private Wealth Management’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-500	Closed	-$1.25K	–	723
2023 Q4	$1.25K	Hold	500	–	–	﹤0.01%	658
2023 Q3	$1.01K	Sell	500 -1,000	-67%	-$2.1K	﹤0.01%	631
2023 Q2	$3.45K	Hold	1,500	–	–	﹤0.01%	538
2023 Q1	$4.54K	Hold	1,500	–	–	﹤0.01%	475
2022 Q4	$3.5K	Hold	1,500	–	–	﹤0.01%	515
2022 Q3	$3K	Hold	1,500	–	–	﹤0.01%	535
2022 Q2	$4K	Hold	1,500	–	–	﹤0.01%	531
2022 Q1	$4K	Hold	1,500	–	–	﹤0.01%	576
2021 Q4	$6K	Buy	+1,500	New	+$5.83K	﹤0.01%	484

Other funds holding ABUS

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

FCM

FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Blue Bell Private Wealth Management's ABUS Position: Q1 2024 in Review

Blue Bell Private Wealth Management sold out of Arbutus Biopharma (ABUS) in Q1 2024, closing a stake of 500 shares — an estimated $1.25K sold.

Blue Bell Private Wealth Management first reported a position in ABUS in Q4 2021 and held it in 9 quarters. The position peaked at $6K in Q4 2021. 119 funds tracked by Wall St. Rank hold ABUS as of Q1 2024.

Blue Bell Private Wealth Management reported no remaining Arbutus Biopharma position as of Q1 2024 after selling out during the quarter.
Blue Bell Private Wealth Management sold 500 Arbutus Biopharma shares in Q1 2024, an estimated $1.25K.
Blue Bell Private Wealth Management first reported a position in Arbutus Biopharma in Q4 2021 and held it in 9 quarters.
Blue Bell Private Wealth Management's Arbutus Biopharma position peaked at $6K in Q4 2021.
119 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2024.

Based on Blue Bell Private Wealth Management's 13F filing for Q1 2024, filed 24 Apr 2024.